Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. - Trigo,J.; Hitt,R.; Koralewski,P.; Diaz-Rubio,E.; Rolland,F.; Knecht,R.; Amellal,N.; Bessa,E.H.; Baselga,J.; Vermorken,J.B. (J Clin Oncol, 2004)